Treatment of fibrosis with interleukin-11 antibody
Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.
1. A method of treating a disease or condition characterised by fibrosis of the liver in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.
2. The method according to claim 1 , wherein the disease or condition is associated with liver cirrhosis.
3. The method according to claim 1 , wherein the disease or condition is selected from the group consisting of: non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), and schistosomal liver disease.
4. The method according to claim 1 , wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.
5. The method according to claim 1 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.
6. The method according to claim 1 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.
7. The method according to claim 1 , wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.
8. A method of treating a disease or condition characterised by fibrosis selected from the group consisting of: non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), schistosomal liver disease and liver cirrhosis in a human subject, the method comprising administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 (IL-11) antibody which is capable of inhibiting IL-11 mediated signaling.
9. The method according to claim 8 , wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.
10. The method according to claim 8 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.
11. The method according to claim 8 , wherein the method comprises administering said antibody to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.
12. The method according to claim 8 , wherein the method comprises determining whether IL-11 or IL-11R expression is upregulated in the subject and administering said antibody to a subject in which IL-11 or IL-11R expression is upregulated.